Perigon Wealth Management 13F: Cuts LLY Stake by $12M

Perigon Wealth Management lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 28.7% during the quarter, according to a Form 13F filing with the SEC on October 22, 2026. The firm sold 10,705 shares of the drug manufacturer during the period, leaving it with 26,608 shares worth approximately $30,786,964.

LLY Eli Lilly and Company

$1,306.74 ▲ +21.54% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in Perigon Wealth Management's Eli Lilly Position

Perigon Wealth Management trimmed its investment in Eli Lilly and Company significantly over the quarter. The fund started the period with 37,313 shares and finished with 26,608 shares after the 10,705-share reduction.

Other Institutional Activity in Eli Lilly

Other major funds also adjusted their positions in Eli Lilly and Company during the filing period. True North Advisors grew its holdings by 1,108 shares, ending with 4,217 shares worth about $4,879,120 after a 35.6% increase. Midwest Trust lifted its stake by 5,069 shares to hold 73,312 shares valued at about $84,827,891, marking a 7.4% increase. Symphony Financial grew its holdings by 1,205 shares, ending with 7,802 shares worth about $9,191,438 after an 18.3% increase. Strategic Blueprint lowered its stake by 785 shares, finishing with 12,911 shares valued at about $14,938,745 following a 5.7% decrease. Meanwhile, Lilly Endowment, Inc reduced its massive holding by 307,272 shares to hold 90,066,978 shares worth about $117,689,614,205, a 0.3% trim.

Eli Lilly and Company Stock Up 1.8%

Eli Lilly and Company shares recently traded around $1,306.74 as of October 23, 2026, staying close to the closing price of $1306.69 recorded on the October 22 filing date. The stock trades above both its 50-day moving average of $1,183.59 and its 200-day moving average of $1,082.90. The share price sits slightly below its 52-week high of $1,311.75.

Recent Earnings

Eli Lilly and Company posted $79.67 billion in trailing-twelve-month revenue alongside earnings of $29.79 per share. The healthcare company reported a net profit margin of 33.5% and a return on equity of 102.3%. The next quarterly earnings report is scheduled for October 29, 2026.

Dividend

Eli Lilly and Company pays an annual dividend rate of $6.92 per share, which represents a dividend yield of 0.54% based on recent pricing. The company maintains a dividend payout ratio of 21.7%.

Insider Buying and Selling at Eli Lilly and Company

Insiders at Eli Lilly and Company completed several transactions ahead of the filing. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at a price of $1,190.00 for a total value of $5,950,000. Officer Donald A Zakrowski sold 2,000 shares on August 10, 2026, at $1,185.01 per share totaling $2,370,020. Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, at $1,175.10 per share for a total of $7,638,150.

Analysts Set New Price Targets

Wall Street analysts updated their views on Eli Lilly and Company ahead of the filing. JP Morgan maintained an Overweight rating and raised its target from $1400.00 to $1500.00 on September 28, 2026. Morgan Stanley kept an Overweight rating while lifting its target from $1419.00 to $1430.00 on October 7, 2026. Cantor Fitzgerald maintained an Overweight rating and moved its target from $1410.00 to $1440.00 on October 8, 2026. RBC Capital reiterated an Outperform rating with a $1500.00 target on October 10, 2026. Leerink Partners kept an Outperform rating and adjusted its target from $1309.00 to $1316.00 on October 21, 2026. Overall, the company holds a consensus buy rating across 30 analyst opinions with a mean price target of $1,331.55.

About Eli Lilly

Eli Lilly and Company is a major healthcare business headquartered in Indianapolis, Indiana. The company discovers, develops, manufactures, and markets human pharmaceutical products globally. Its treatments address common health conditions across international markets.

Bottom Line

Investors will look toward the upcoming earnings release on October 29, 2026, for fresh updates on financial performance. Future institutional filings will show whether other wealth management firms follow Perigon in trimming positions.